- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02064036
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (CCRO025)
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with unfavorable intermediate and high risk localized prostate cancer.
Our primary objective is to assess the feasibility and safety of a treatment strategy incorporating whole pelvic IMRT followed by an SBRT boost to the prostate with neoadjuvant, concurrent, and adjuvant androgen deprivation for a total of 28 months for men with unfavorable intermediate or high risk localized prostate cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to assess the feasibility and safety of a treatment strategy incorporating whole pelvic IMRT followed by an SBRT boost to the prostate with neoadjuvant, concurrent, and adjuvant androgen deprivation for a total of 28 months for men with unfavorable intermediate or high risk localized prostate cancer.
The secondary objective is to assess biochemical control at 24 months following the experimental treatment strategy by the "Phoenix definition". Patients not meeting these prostate-specific antigen (PSA) criteria (Phoenix Definition) for failure who undergo salvage therapies (such as androgen deprivation therapy (ADT), radical prostatectomy or brachytherapy, or Cryosurgery) should also be declared as failures at the time a positive biopsy is obtained or salvage therapy is administered, whichever comes first.
Another secondary objective is to assess toxicity of the experimental treatment approach as scored by the Common Terminology Criteria for Adverse Events The third secondary objective is to assess prostate organ motion during hypofractionated radiotherapy. To assess motion of the prostate during the protracted delivery of hypofractionated radiotherapy as assessed by implanted electromagnetic transponder beacons.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis Sacramento Cancer Center Dept of Radiation Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence
- History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.
- Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MRI), (but not by nodal sampling, or dissection) within 90 days prior to registration.
- Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 2.0 cm.
- No evidence of bone metastases (M0) on bone scan within 90 days prior to registration.
- Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis.
- Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 12 weeks (90 days) prior to registration.
- Study entry PSA should not be obtained during the following time frames: (1) 10-day period following prostate biopsy; (2) following initiation of hormonal therapy; (3) within 30 days after discontinuation of finasteride; (4) within 90 days after discontinuation of dutasteride.
- Zubrod Performance Status 0-2
- Complete blood count (CBC)/differential obtained within 2 weeks (14 days) prior to registration on study, with adequate bone marrow function
- Patient must be able to provide study specific informed consent prior to study entry.
Exclusion Criteria:
- Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 2 years.
- Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
- Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
- Previous hormonal therapy
- Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is ≤ 60 days prior to the date of registration.
- Use of finasteride within 30 days prior to registration
- Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration
- Previous or concurrent cytotoxic chemotherapy for prostate cancer; note that prior chemotherapy for a different cancer is allowable. See Section 3.2.1.
- Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
- Severe, active co-morbidity including heart issues, infection and liver problems
- Patients who are sexually active and not willing/able to use medically acceptable forms of contraception
- Prior allergic reaction to the hormones involved in this protocol
- Patients status-post a negative lymph node dissection are not eligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single
Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
|
Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
Other Names:
Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Other Names:
Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Assessment
Time Frame: 24 months
|
Tumors will be assessed using the American Joint Committee on Cancer (AJCC) Staging System, 7th Edition.
This system consists of the following subscales: the extent of the primary tumor (T category), whether the cancer has spread to nearby lymph nodes (N category), the absence or presence of distant metastasis (M category), the PSA level at the time of diagnosis, and the Gleason score, based on the prostate biopsy (or surgery).
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Zubrod Performance Scale
Time Frame: Weekly during radiation treatment; every three months during hormone therapy; every six months for 3 yrs after hormone therapy
|
This is a scale used to evaluate the patient's performance status is an attempt to quantify cancer patients' general well-being and activities of daily life.
|
Weekly during radiation treatment; every three months during hormone therapy; every six months for 3 yrs after hormone therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Valicenti, MD, University of California, Davis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Adenocarcinoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Androgen Antagonists
- Leuprolide
- Goserelin
- Bicalutamide
Other Study ID Numbers
- 421870
- CCRO025 (Other Identifier: UC Davis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Prostate
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
Centre Georges Francois LeclercActive, not recruiting
-
Sir Mortimer B. Davis - Jewish General HospitalAbbottRecruitingAdjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma ProstateAdenocarcinoma of the ProstateCanada
-
Virginia Commonwealth UniversityCompletedAdenocarcinoma of the ProstateUnited States
-
University Hospital, BrestRecruitingAdenocarcinoma of the ProstateFrance
-
Centre Hospitalier Universitaire de NīmesActive, not recruitingAdenocarcinoma of the ProstateFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedAdenocarcinoma of the ProstateUnited States
-
James TaylorCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...United States Department of DefenseCompletedLocally Confined Adenocarcinoma of the ProstateUnited States
Clinical Trials on Stereotactic Radiosurgical Boost
-
University Hospital OstravaUniversity of Ostrava; Hospital Podlesi; Hospital Novy JicinCompleted
-
University of California, San FranciscoNorth American Gamma Knife ConsortiumTerminatedBrain MetastasesUnited States
-
University of California, San FranciscoNorth American Gamma Knife ConsortiumWithdrawnBrain MetastasesUnited States
-
Royal North Shore HospitalCompleted
-
Ronald McGarryCompletedLung CancerUnited States
-
Boston Medical CenterActive, not recruitingProstate CancerUnited States
-
CancerCare ManitobaTerminatedProstatic NeoplasmsCanada
-
MemorialCare Health SystemRecruiting
-
University of MiamiWithdrawn
-
IRCCS San RaffaeleRecruitingOligometastatic DiseaseItaly